Hsu Yao-Chun
Dig Dis. 2023 Mar 28. doi: 10.1159/000530349.
Chronic liver disease (CLD) affects approximately 1.5 billion people around the world.1 Non-alcoholic fatty liver disease (NAFLD) is the most common CLD that accounts for 59% of prevalent cases, followed by hepatitis B virus (HBV) infection (29%) and hepatitis C virus infection (9%).2 CLD is a silent killer characterized by insidious progression in hepatic necroinflammation and fibrosis that can culminate in cirrhosis and increase the risk of primary liver cancer. According to the Global Burden of Disease study, there were 2.1 million deaths attributable to CLD in 2017, with cirrhosis and liver cancer respectively responsible for 62% and 38% of the mortality.3.
慢性肝病（CLD）影响着全球约15亿人。非酒精性脂肪性肝病（NAFLD）是最常见的慢性肝病，占流行病例的59%，其次是乙型肝炎病毒（HBV）感染（29%）和丙型肝炎病毒感染（9%）。慢性肝病是一种无声杀手，其特征是肝脏坏死性炎症和纤维化隐匿进展，最终可发展为肝硬化并增加原发性肝癌的风险。根据全球疾病负担研究，2017年有210万人死于慢性肝病，其中肝硬化和肝癌分别占死亡率的62%和38%。
